B+
Bull case
25%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
MRK
MerckCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$136.72
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$115.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+52.6
Score
AI commentary
News tone is mixed-to-positive: dated company milestones include the July 16 LIPFENDRA approval and August 4 earnings release, while secondary coverage includes a negative clinical-program report. Social coverage is unavailable, and post-print analyst revisions and precise price reaction are not established; this is a constructive but monitoring-oriented view.
RankAlpha Sentiment Codex - 2026-08-07
Open post-earnings memoEvidence flagged
Forward visibility is limited, so this memo should be read as a lower-conviction monitoring view rather than a catalyst-driven call.; no forward-looking company-specific catalyst is supported by primary-source evidence; high-coverage report lacks a dated company-specific catalyst beyond generic cadence
Impact
tentative
Confidence
-
AI events
2026-07-16catalystLIPFENDRA FDA approval milestoneMedium impact
Merck announced FDA approval of LIPFENDRA on July 16, 2026, making it the first once-daily oral PCSK9 inhibitor approved in the United States. The milestone creates a cardiometabolic launch opportunity, but commercial uptake is not yet evidenced in the packet and remains execution-dependent. [#IR-2026-07-16] [#SEC-8K-2026-08-04]
2026-08-04eventQ2 earnings delivered a raised sales outlookMedium impact
Merck reported Q2 sales of $16.607 billion, up 5%, with KEYTRUDA/KEYTRUDA QLEX sales of $8.366 billion and WINREVAIR sales up 75%. The company raised its FY2026 sales range to $66.3-$67.3 billion; EPS remains affected by Terns acquisition charges. [#SEC-8K-2026-08-04] [#8-K-2026-08-04]
2026-08-04catalystLaunch growth and pipeline diversificationMedium impact
Management highlighted initial KEYTRUDA QLEX uptake, strong WINREVAIR growth, positive TroFuse-005 data, and positive Phase 3 results for the once-weekly oral HIV regimen with Gilead. Further value depends on regulatory, clinical, and commercial follow-through. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology